The synergistic treatment effectively increases CD8+ T cell levels at tumor sites, induces TAMs polarization, and reduces the hypoxia-induced tumor infiltration of TAMs, NanoMnSor also reprograms the immunosuppressive TME, improving the effect of anti-PD-1 and systemic anti-tumor immune response for the treatment of cancer. This evidence concerns the gene CD8A and cancer.